Risk/benefit in prophylaxis and treatment of secondary hyperparathyroidism. A comparison of two low calcium peritoneal dialysis fluids

Nephrology Dialysis Transplantation

Volumn 11, Issue SUPPL. 3, 1996, Pages 47-49

  Bro, S ^a   Brandi, L ^a   Olgaard, K ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Aluminium; Dialysate calcium; Plasma calcium; Plasma iPTH; Plasma phosphate

Indexed keywords

ALFACALCIDOL; CALCIUM ION; DIALYSIS FLUID; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT;

CALCIUM BLOOD LEVEL; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY HYPERPARATHYROIDISM;

EID: 0029756488     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/11.supp3.47     Document Type: Conference Paper

References (1)

1. Quarles LD, Lobaugh B, Murphy G. Intact PTH overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150